Phreesia, Inc. (NYSE: PHR) Stock Competitors & Peer Comparison

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, GEHC has a market cap of 33.7B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while GEHC trades at $74.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas GEHC's P/E ratio is 16.36. In terms of profitability, PHR's ROE is +0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PHR is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PHR.Check GEHC's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas GEHCV's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, PHR is less volatile compared to GEHCV. This indicates lower risk in terms of short-term price fluctuations for PHR.Check GEHCV's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, BTSG has a market cap of 11.6B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while BTSG trades at $59.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas BTSG's P/E ratio is 47.85. In terms of profitability, PHR's ROE is +0.03%, compared to BTSG's ROE of +0.15%. Regarding short-term risk, PHR is less volatile compared to BTSG. This indicates lower risk in terms of short-term price fluctuations for PHR.Check BTSG's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, TEM has a market cap of 10.7B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while TEM trades at $66.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas TEM's P/E ratio is -122.34. In terms of profitability, PHR's ROE is +0.03%, compared to TEM's ROE of -0.55%. Regarding short-term risk, PHR is less volatile compared to TEM. This indicates lower risk in terms of short-term price fluctuations for PHR.Check TEM's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SGFY's P/E ratio is 70.91. In terms of profitability, PHR's ROE is +0.03%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, PHR is more volatile compared to SGFY. This indicates higher risk in terms of short-term price fluctuations for PHR.Check SGFY's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, HQY has a market cap of 8.7B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while HQY trades at $105.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas HQY's P/E ratio is 24.29. In terms of profitability, PHR's ROE is +0.03%, compared to HQY's ROE of +0.11%. Regarding short-term risk, PHR is less volatile compared to HQY. This indicates lower risk in terms of short-term price fluctuations for PHR.Check HQY's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, TXG has a market cap of 7.9B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while TXG trades at $62.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas TXG's P/E ratio is -365.82. In terms of profitability, PHR's ROE is +0.03%, compared to TXG's ROE of -0.09%. Regarding short-term risk, PHR is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for PHR.Check TXG's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, HNGE has a market cap of 6.8B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while HNGE trades at $87.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas HNGE's P/E ratio is 47.31. In terms of profitability, PHR's ROE is +0.03%, compared to HNGE's ROE of +0.30%. Regarding short-term risk, PHR is less volatile compared to HNGE. This indicates lower risk in terms of short-term price fluctuations for PHR.Check HNGE's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas RCM's P/E ratio is -102.21. In terms of profitability, PHR's ROE is +0.03%, compared to RCM's ROE of +0.00%. Regarding short-term risk, PHR is more volatile compared to RCM. This indicates higher risk in terms of short-term price fluctuations for PHR.Check RCM's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, DOCS has a market cap of 4.8B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while DOCS trades at $26.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas DOCS's P/E ratio is 16.84. In terms of profitability, PHR's ROE is +0.03%, compared to DOCS's ROE of +0.17%. Regarding short-term risk, PHR is less volatile compared to DOCS. This indicates lower risk in terms of short-term price fluctuations for PHR.Check DOCS's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, WAY has a market cap of 4.8B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while WAY trades at $24.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas WAY's P/E ratio is 16.45. In terms of profitability, PHR's ROE is +0.03%, compared to WAY's ROE of +0.04%. Regarding short-term risk, PHR is more volatile compared to WAY. This indicates higher risk in terms of short-term price fluctuations for PHR.Check WAY's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, HTFL has a market cap of 3.9B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while HTFL trades at $47.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas HTFL's P/E ratio is -22.65. In terms of profitability, PHR's ROE is +0.03%, compared to HTFL's ROE of -0.42%. Regarding short-term risk, PHR is less volatile compared to HTFL. This indicates lower risk in terms of short-term price fluctuations for PHR.Check HTFL's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ONEM's P/E ratio is -7.77. In terms of profitability, PHR's ROE is +0.03%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, PHR is less volatile compared to ONEM. This indicates lower risk in terms of short-term price fluctuations for PHR.Check ONEM's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, PRVA has a market cap of 2.7B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while PRVA trades at $21.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas PRVA's P/E ratio is 102.33. In terms of profitability, PHR's ROE is +0.03%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, PHR is more volatile compared to PRVA. This indicates higher risk in terms of short-term price fluctuations for PHR.Check PRVA's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, WGS has a market cap of 2.4B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while WGS trades at $81.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas WGS's P/E ratio is 221.25. In terms of profitability, PHR's ROE is +0.03%, compared to WGS's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for PHR.Check WGS's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while PGNY trades at $25.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas PGNY's P/E ratio is 18.50. In terms of profitability, PHR's ROE is +0.03%, compared to PGNY's ROE of +0.16%. Regarding short-term risk, PHR is less volatile compared to PGNY. This indicates lower risk in terms of short-term price fluctuations for PHR.Check PGNY's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas NXGN's P/E ratio is -266.00. In terms of profitability, PHR's ROE is +0.03%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, PHR is more volatile compared to NXGN. This indicates higher risk in terms of short-term price fluctuations for PHR.Check NXGN's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, OMDA has a market cap of 1.5B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while OMDA trades at $24.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas OMDA's P/E ratio is 349.57. In terms of profitability, PHR's ROE is +0.03%, compared to OMDA's ROE of +0.02%. Regarding short-term risk, PHR is less volatile compared to OMDA. This indicates lower risk in terms of short-term price fluctuations for PHR.Check OMDA's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas AGTI's P/E ratio is -71.79. In terms of profitability, PHR's ROE is +0.03%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, PHR is more volatile compared to AGTI. This indicates higher risk in terms of short-term price fluctuations for PHR.Check AGTI's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CERT has a market cap of 1.3B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CERT trades at $8.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CERT's P/E ratio is 20.90. In terms of profitability, PHR's ROE is +0.03%, compared to CERT's ROE of -0.07%. Regarding short-term risk, PHR is less volatile compared to CERT. This indicates lower risk in terms of short-term price fluctuations for PHR.Check CERT's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, GDRX has a market cap of 1.2B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while GDRX trades at $3.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas GDRX's P/E ratio is 11.06. In terms of profitability, PHR's ROE is +0.03%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, PHR is more volatile compared to GDRX. This indicates higher risk in terms of short-term price fluctuations for PHR.Check GDRX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while TDOC trades at $6.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas TDOC's P/E ratio is -7.40. In terms of profitability, PHR's ROE is +0.03%, compared to TDOC's ROE of -0.13%. Regarding short-term risk, PHR is less volatile compared to TDOC. This indicates lower risk in terms of short-term price fluctuations for PHR.Check TDOC's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CCLDO trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CCLDO's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, PHR is more volatile compared to CCLDO. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CCLDO's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, HSTM has a market cap of 834.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while HSTM trades at $28.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas HSTM's P/E ratio is 35.25. In terms of profitability, PHR's ROE is +0.03%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, PHR is more volatile compared to HSTM. This indicates higher risk in terms of short-term price fluctuations for PHR.Check HSTM's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SOPH has a market cap of 694.7M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SOPH trades at $8.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SOPH's P/E ratio is -7.46. In terms of profitability, PHR's ROE is +0.03%, compared to SOPH's ROE of -1.37%. Regarding short-term risk, PHR is less volatile compared to SOPH. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SOPH's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MPLN-WT's ROE of +1.40%. Regarding short-term risk, PHR is less volatile compared to MPLN-WT. This indicates lower risk in terms of short-term price fluctuations for PHR.Check MPLN-WT's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CTEV has a market cap of 605.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CTEV trades at $34.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CTEV's P/E ratio is -2.09. In terms of profitability, PHR's ROE is +0.03%, compared to CTEV's ROE of +1.40%. Regarding short-term risk, PHR is less volatile compared to CTEV. This indicates lower risk in terms of short-term price fluctuations for PHR.Check CTEV's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ACCD's P/E ratio is -3.08. In terms of profitability, PHR's ROE is +0.03%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, PHR is more volatile compared to ACCD. This indicates higher risk in terms of short-term price fluctuations for PHR.Check ACCD's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SHCR's P/E ratio is -3.76. In terms of profitability, PHR's ROE is +0.03%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, PHR is more volatile compared to SHCR. This indicates higher risk in terms of short-term price fluctuations for PHR.Check SHCR's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, EVH has a market cap of 516.9M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while EVH trades at $4.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas EVH's P/E ratio is 35.35. In terms of profitability, PHR's ROE is +0.03%, compared to EVH's ROE of -0.99%. Regarding short-term risk, PHR is less volatile compared to EVH. This indicates lower risk in terms of short-term price fluctuations for PHR.Check EVH's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, NRC has a market cap of 496M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while NRC trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas NRC's P/E ratio is 26.84. In terms of profitability, PHR's ROE is +0.03%, compared to NRC's ROE of +0.48%. Regarding short-term risk, PHR is less volatile compared to NRC. This indicates lower risk in terms of short-term price fluctuations for PHR.Check NRC's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SLGC's P/E ratio is -3.04. In terms of profitability, PHR's ROE is +0.03%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, PHR is less volatile compared to SLGC. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SLGC's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, PHR's ROE is +0.03%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, PHR is less volatile compared to SLGCW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SLGCW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, TBRG has a market cap of 393.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while TBRG trades at $26.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas TBRG's P/E ratio is 9.37. In terms of profitability, PHR's ROE is +0.03%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, PHR is more volatile compared to TBRG. This indicates higher risk in terms of short-term price fluctuations for PHR.Check TBRG's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MPLN's P/E ratio is -0.23. In terms of profitability, PHR's ROE is +0.03%, compared to MPLN's ROE of +1.40%. Regarding short-term risk, PHR is less volatile compared to MPLN. This indicates lower risk in terms of short-term price fluctuations for PHR.Check MPLN's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SY has a market cap of 313.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SY trades at $2.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SY's P/E ratio is -7.24. In terms of profitability, PHR's ROE is +0.03%, compared to SY's ROE of -0.16%. Regarding short-term risk, PHR is less volatile compared to SY. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SY's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas TRHC's P/E ratio is -4.27. In terms of profitability, PHR's ROE is +0.03%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, PHR is more volatile compared to TRHC. This indicates higher risk in terms of short-term price fluctuations for PHR.Check TRHC's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SMFR's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to SMFR's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to SMFR. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SMFR's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SPOK has a market cap of 218.9M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SPOK trades at $10.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SPOK's P/E ratio is 17.47. In terms of profitability, PHR's ROE is +0.03%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, PHR is more volatile compared to SPOK. This indicates higher risk in terms of short-term price fluctuations for PHR.Check SPOK's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, AMWL has a market cap of 209.7M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while AMWL trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas AMWL's P/E ratio is -2.79. In terms of profitability, PHR's ROE is +0.03%, compared to AMWL's ROE of -0.33%. Regarding short-term risk, PHR is less volatile compared to AMWL. This indicates lower risk in terms of short-term price fluctuations for PHR.Check AMWL's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, OPRX has a market cap of 150.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while OPRX trades at $8.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas OPRX's P/E ratio is 7.35. In terms of profitability, PHR's ROE is +0.03%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, PHR is less volatile compared to OPRX. This indicates lower risk in terms of short-term price fluctuations for PHR.Check OPRX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CPSI's P/E ratio is -183.80. In terms of profitability, PHR's ROE is +0.03%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, PHR is less volatile compared to CPSI. This indicates lower risk in terms of short-term price fluctuations for PHR.Check CPSI's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, HCAT has a market cap of 124.9M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while HCAT trades at $1.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas HCAT's P/E ratio is 8.45. In terms of profitability, PHR's ROE is +0.03%, compared to HCAT's ROE of -1.30%. Regarding short-term risk, PHR is less volatile compared to HCAT. This indicates lower risk in terms of short-term price fluctuations for PHR.Check HCAT's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas AUGX's P/E ratio is -4.99. In terms of profitability, PHR's ROE is +0.03%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, PHR is more volatile compared to AUGX. This indicates higher risk in terms of short-term price fluctuations for PHR.Check AUGX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CCLD has a market cap of 112.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CCLD trades at $2.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CCLD's P/E ratio is 10.15. In terms of profitability, PHR's ROE is +0.03%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, PHR is less volatile compared to CCLD. This indicates lower risk in terms of short-term price fluctuations for PHR.Check CCLD's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, WORX has a market cap of 88M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while WORX trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas WORX's P/E ratio is -6.40. In terms of profitability, PHR's ROE is +0.03%, compared to WORX's ROE of -0.35%. Regarding short-term risk, PHR is less volatile compared to WORX. This indicates lower risk in terms of short-term price fluctuations for PHR.Check WORX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, DH has a market cap of 75.8M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while DH trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas DH's P/E ratio is 2.76. In terms of profitability, PHR's ROE is +0.03%, compared to DH's ROE of -0.79%. Regarding short-term risk, PHR is less volatile compared to DH. This indicates lower risk in terms of short-term price fluctuations for PHR.Check DH's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas FORA's P/E ratio is -24.11. In terms of profitability, PHR's ROE is +0.03%, compared to FORA's ROE of -0.17%. Regarding short-term risk, PHR is more volatile compared to FORA. This indicates higher risk in terms of short-term price fluctuations for PHR.Check FORA's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CCLDP's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, PHR is less volatile compared to CCLDP. This indicates lower risk in terms of short-term price fluctuations for PHR.Check CCLDP's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SNCE's P/E ratio is -0.27. In terms of profitability, PHR's ROE is +0.03%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, PHR is more volatile compared to SNCE. This indicates higher risk in terms of short-term price fluctuations for PHR.Check SNCE's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas AKLI's P/E ratio is -0.71. In terms of profitability, PHR's ROE is +0.03%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, PHR is more volatile compared to AKLI. This indicates higher risk in terms of short-term price fluctuations for PHR.Check AKLI's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SHLT's P/E ratio is -3.87. In terms of profitability, PHR's ROE is +0.03%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, PHR is more volatile compared to SHLT. This indicates higher risk in terms of short-term price fluctuations for PHR.Check SHLT's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ONMD has a market cap of 33.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ONMD trades at $0.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ONMD's P/E ratio is -3.89. In terms of profitability, PHR's ROE is +0.03%, compared to ONMD's ROE of +2.35%. Regarding short-term risk, PHR is less volatile compared to ONMD. This indicates lower risk in terms of short-term price fluctuations for PHR.Check ONMD's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, PHR is less volatile compared to SHCRW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SHCRW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ONMDW has a market cap of 31.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ONMDW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ONMDW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to ONMDW's ROE of +2.35%. Regarding short-term risk, PHR is more volatile compared to ONMDW. This indicates higher risk in terms of short-term price fluctuations for PHR.Check ONMDW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas STRM's P/E ratio is -2.40. In terms of profitability, PHR's ROE is +0.03%, compared to STRM's ROE of -0.65%. Regarding short-term risk, PHR is more volatile compared to STRM. This indicates higher risk in terms of short-term price fluctuations for PHR.Check STRM's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas RNLX's P/E ratio is -0.33. In terms of profitability, PHR's ROE is +0.03%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, PHR is less volatile compared to RNLX. This indicates lower risk in terms of short-term price fluctuations for PHR.Check RNLX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas LIFW's P/E ratio is -0.02. In terms of profitability, PHR's ROE is +0.03%, compared to LIFW's ROE of +1.56%. Regarding short-term risk, PHR is more volatile compared to LIFW. This indicates higher risk in terms of short-term price fluctuations for PHR.Check LIFW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SCNX has a market cap of 19.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SCNX trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SCNX's P/E ratio is -0.19. In terms of profitability, PHR's ROE is +0.03%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, PHR is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SCNX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas BBLN's P/E ratio is -0.04. In terms of profitability, PHR's ROE is +0.03%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, PHR is less volatile compared to BBLN. This indicates lower risk in terms of short-term price fluctuations for PHR.Check BBLN's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, BFRG has a market cap of 10.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while BFRG trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas BFRG's P/E ratio is -1.06. In terms of profitability, PHR's ROE is +0.03%, compared to BFRG's ROE of -1.50%. Regarding short-term risk, PHR is less volatile compared to BFRG. This indicates lower risk in terms of short-term price fluctuations for PHR.Check BFRG's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ETAO's P/E ratio is -0.01. In terms of profitability, PHR's ROE is +0.03%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, PHR is less volatile compared to ETAO. This indicates lower risk in terms of short-term price fluctuations for PHR.Check ETAO's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, BEATW has a market cap of 8.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while BEATW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas BEATW's P/E ratio is -0.02. In terms of profitability, PHR's ROE is +0.03%, compared to BEATW's ROE of -6.87%. Regarding short-term risk, PHR is less volatile compared to BEATW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check BEATW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MGRX has a market cap of 7.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MGRX trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MGRX's P/E ratio is -0.31. In terms of profitability, PHR's ROE is +0.03%, compared to MGRX's ROE of -1.06%. Regarding short-term risk, PHR is less volatile compared to MGRX. This indicates lower risk in terms of short-term price fluctuations for PHR.Check MGRX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, PHR is less volatile compared to UPH-WT. This indicates lower risk in terms of short-term price fluctuations for PHR.Check UPH-WT's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas UPH's P/E ratio is -0.07. In terms of profitability, PHR's ROE is +0.03%, compared to UPH's ROE of -1.05%. Regarding short-term risk, PHR is less volatile compared to UPH. This indicates lower risk in terms of short-term price fluctuations for PHR.Check UPH's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas PEAR's P/E ratio is -0.08. In terms of profitability, PHR's ROE is +0.03%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to PEAR. This indicates lower risk in terms of short-term price fluctuations for PHR.Check PEAR's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas PEARW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to PEARW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check PEARW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas OTRK's P/E ratio is -0.02. In terms of profitability, PHR's ROE is +0.03%, compared to OTRK's ROE of -2.11%. Regarding short-term risk, PHR is more volatile compared to OTRK. This indicates higher risk in terms of short-term price fluctuations for PHR.Check OTRK's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CMAX's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, PHR is more volatile compared to CMAX. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CMAX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ACON has a market cap of 1.5M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ACON trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ACON's P/E ratio is -0.31. In terms of profitability, PHR's ROE is +0.03%, compared to ACON's ROE of -0.59%. Regarding short-term risk, PHR is less volatile compared to ACON. This indicates lower risk in terms of short-term price fluctuations for PHR.Check ACON's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to LIFWZ's ROE of +1.56%. Regarding short-term risk, PHR is more volatile compared to LIFWZ. This indicates higher risk in terms of short-term price fluctuations for PHR.Check LIFWZ's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, HCTI has a market cap of 1.1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while HCTI trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas HCTI's P/E ratio is -0.12. In terms of profitability, PHR's ROE is +0.03%, compared to HCTI's ROE of -0.56%. Regarding short-term risk, PHR is less volatile compared to HCTI. This indicates lower risk in terms of short-term price fluctuations for PHR.Check HCTI's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, EUDAW has a market cap of 1M. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while EUDAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas EUDAW's P/E ratio is 0.03. In terms of profitability, PHR's ROE is +0.03%, compared to EUDAW's ROE of +1.20%. Regarding short-term risk, PHR is less volatile compared to EUDAW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check EUDAW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, VSEEW has a market cap of 560.3K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while VSEEW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas VSEEW's P/E ratio is -0.04. In terms of profitability, PHR's ROE is +0.03%, compared to VSEEW's ROE of -4.02%. Regarding short-term risk, PHR is less volatile compared to VSEEW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check VSEEW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MSPRZ's ROE of +1.56%. Regarding short-term risk, PHR is less volatile compared to MSPRZ. This indicates lower risk in terms of short-term price fluctuations for PHR.Check MSPRZ's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, VSEE has a market cap of 414.4K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while VSEE trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas VSEE's P/E ratio is -0.05. In terms of profitability, PHR's ROE is +0.03%, compared to VSEE's ROE of -4.02%. Regarding short-term risk, PHR is less volatile compared to VSEE. This indicates lower risk in terms of short-term price fluctuations for PHR.Check VSEE's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas KERN's P/E ratio is -0.01. In terms of profitability, PHR's ROE is +0.03%, compared to KERN's ROE of -0.20%. Regarding short-term risk, PHR is less volatile compared to KERN. This indicates lower risk in terms of short-term price fluctuations for PHR.Check KERN's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas KERNW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to KERNW's ROE of -0.20%. Regarding short-term risk, PHR is less volatile compared to KERNW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check KERNW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas LIFWW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to LIFWW's ROE of +1.56%. Regarding short-term risk, PHR is more volatile compared to LIFWW. This indicates higher risk in terms of short-term price fluctuations for PHR.Check LIFWW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CMAXW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, PHR is more volatile compared to CMAXW. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CMAXW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ZCMD has a market cap of 35.1K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ZCMD trades at $0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, PHR's ROE is +0.03%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, PHR is less volatile compared to ZCMD. This indicates lower risk in terms of short-term price fluctuations for PHR.Check ZCMD's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, ACONW has a market cap of 16K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while ACONW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas ACONW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to ACONW's ROE of -0.59%. Regarding short-term risk, PHR is more volatile compared to ACONW. This indicates higher risk in terms of short-term price fluctuations for PHR.Check ACONW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while WGSWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, PHR is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for PHR.Check WGSWW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, NAVA has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while NAVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas NAVA's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, PHR is not fully comparable compared to NAVA. This indicates unavailable risk data in terms of short-term price fluctuations for PHR.Check NAVA's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CHNGU's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, PHR is more volatile compared to CHNGU. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CHNGU's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, AFFX has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while AFFX trades at $14.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas AFFX's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, PHR is more volatile compared to AFFX. This indicates higher risk in terms of short-term price fluctuations for PHR.Check AFFX's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, NH has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas NH's P/E ratio is -0.12. In terms of profitability, PHR's ROE is +0.03%, compared to NH's ROE of +0.35%. Regarding short-term risk, PHR is less volatile compared to NH. This indicates lower risk in terms of short-term price fluctuations for PHR.Check NH's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas SMFRW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to SMFRW's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to SMFRW. This indicates lower risk in terms of short-term price fluctuations for PHR.Check SMFRW's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, IMS has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while IMS trades at $31.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas IMS's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to IMS's ROE of +0.27%. Regarding short-term risk, PHR is less volatile compared to IMS. This indicates lower risk in terms of short-term price fluctuations for PHR.Check IMS's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MTBC has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MTBC's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MTBC's ROE of +0.19%. Regarding short-term risk, PHR is less volatile compared to MTBC. This indicates lower risk in terms of short-term price fluctuations for PHR.Check MTBC's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MTBCO's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, PHR is more volatile compared to MTBCO. This indicates higher risk in terms of short-term price fluctuations for PHR.Check MTBCO's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CNVY has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CNVY's P/E ratio is -71.50. In terms of profitability, PHR's ROE is +0.03%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, PHR is more volatile compared to CNVY. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CNVY's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MSPRV's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MSPRV's ROE of N/A. Regarding short-term risk, PHR is less volatile compared to MSPRV. This indicates lower risk in terms of short-term price fluctuations for PHR.Check MSPRV's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, KURIU has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while KURIU trades at $9.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas KURIU's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, PHR is less volatile compared to KURIU. This indicates lower risk in terms of short-term price fluctuations for PHR.Check KURIU's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CSLT has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CSLT's P/E ratio is -37.27. In terms of profitability, PHR's ROE is +0.03%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, PHR is more volatile compared to CSLT. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CSLT's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CHNG has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CHNG's P/E ratio is -152.72. In terms of profitability, PHR's ROE is +0.03%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, PHR is more volatile compared to CHNG. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CHNG's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, MTBCP has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas MTBCP's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, PHR is more volatile compared to MTBCP. This indicates higher risk in terms of short-term price fluctuations for PHR.Check MTBCP's competition here

Phreesia, Inc. (NYSE: PHR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PHR stands at 739M. In comparison, CERN has a market cap of 0. Regarding current trading prices, PHR is priced at $11.98 on the NYSE, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PHR currently has a P/E ratio of 42.70, whereas CERN's P/E ratio is 55.84. In terms of profitability, PHR's ROE is +0.03%, compared to CERN's ROE of +0.14%. Regarding short-term risk, PHR is more volatile compared to CERN. This indicates higher risk in terms of short-term price fluctuations for PHR.Check CERN's competition here